Iron Homeostasis in Patients with Nonalcoholic Fatty Liver Disease
Abstract
Introduction: Serum ferritin correlates with hepatic iron deposition in patients with Non Alcoholic Fatty Liver Disease (NAFLD). Iron removal improves insulin sensitivity thereby delaying the onset of type 2 diabetes mellitus, improves liver function and NAFLD histology.
Objectives: This study was done to assess the iron status in NAFLD patients and its association with fibrosis and metabolic syndrome in NAFLD.
Material and Method: The study was conducted in the Department of Medicine, GTB Hospital, Delhi from November 2017 - October 2019. It was an Analytical, comparative study. Forty patients with NAFLD were selected in the study group and forty healthy subjects with no evidence of fatty liver on ultrasound were selected in the control group. The level of iron parameters recorded in NAFLD patients and the control group were compared using independent t test and p value of <0.05 was considered statistically significant. Assessment of association of various parameters of iron status with the presence of Metabolic Syndrome and fibrosis in NAFLD patients was done using the Chi-Square test.
Result: The parameters of iron status namely serum iron, serum ferritin, transferrin saturation and serum hepcidin were found to be higher in NAFLD patients when compared to controls. This study also observed that there was a statistically significant positive association of serum ferritin with the presence of MetS in NAFLD patients. The study also found that serum hepcidin and serum ferritin have a significant positive association with fibrosis in NAFLD.
Discussion: Assessment of iron status in NAFLD may help in early identification of individuals at high risk of fibrosis and other complications like Mets. Application of iron removal strategies like phlebotomy in such patients might improve IR and NAFLD.
How to cite this article:
Kumar K, Devu R, Avasthi R, Agarwal MP, Sharma S, Tandon A. Iron Homeostasis in Patients with Nonalcoholic Fatty Liver Disease. J Adv Res Med. 2021; 8(2): 6-10.
DOI: https://doi.org/10.24321/2349.7181.202107
References
Chandok N, Minuk G, Wengiel M, Uhanova J. Serum ferritin levels do not predict the stage of underlying
non-alcoholic fatty liver disease. J Gastrointestin Liver Dis. 2012 Mar 1;21(1):53-8. [PubMed] [Google Scholar]
Dai W, Ye L, Liu A, Wen SW, Deng J, Wu X, Lai Z. Prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: a meta-analysis. Medicine. 2017 Sep;96(39):e8179. [PubMed] [Google Scholar]
Das K, Das K, Mukherjee PS, Ghosh A, Ghosh S, Mridha AR, Dhibar T, Bhattacharya B, Bhattacharya D, Manna
B, Dhali GK. Nonobese population in a developing country has a high prevalence of nonalcoholic fatty
liver and significant liver disease. Hepatology. 2010 May;51(5):1593-602. [Google Scholar]
Zelber-Sagi S, Nitzan-Kaluski D, Halpern Z, Oren R. NAFLD and hyperinsulinemia are major determinants of
serum ferritin levels. Jhepatol. 2007 Apr 1;46(4):700-7. [PubMed] [Google Scholar]
Alberti KG, Zimmet P, Shaw J: The metabolic syndrome–a new worldwide definition. Lancet 2005, 366:1059-1062. [PubMed] [Google Scholar]
Kowdley KV, Belt P, Wilson LA, Yeh MM, Neuschwanderâ€Tetri BA, Chalasani N, Sanyal AJ, Nelson JE, NASH Clinical Research Network. Serum ferritin is an independent predictor of histologic severity and advanced fibrosis
in patients with nonalcoholic fatty liver disease. Hepatology. 2012 Jan;55(1):77-85. [PubMed] [Google
Scholar]
Angulo P, George J, Day CP, Vanni E, Russell L, Anna C, Liaquat H, Mezzabotta L, Lee E, Bugianesi E. Serum
ferritin levels lack diagnostic accuracy for liver fibrosis in patients with nonalcoholic fatty liver disease. Clin
Gastroenterol Hepatol. 2014 Jul 1;12(7):1163-9. [PubMed] [Google Scholar]
Chitturi S, Weltman M, Farrell GC, McDonald D, Liddle C, Samarasinghe D, Lin R, Abeygunasekera S, George J.
HFE mutations, hepatic iron, and fibrosis: ethnicâ€specific association of NASH with C282Y but not with fibrotic
severity. Hepatology. 2002 Jul;36(1):142-9. [PubMed] [Google Scholar]
Valenti L, Fracanzani AL, Bugianesi E, Dongiovanni P, Galmozzi E, Vanni E, Canavesi E, Lattuada E, Roviaro G,
Marchesini G, Fargion S. HFE genotype, parenchymal iron accumulation, and liver fibrosis in patients with
nonalcoholic fatty liver disease. Gastroenterology. 2010 Mar 1;138(3):905-12. [PubMed] [Google Scholar]
Hoki T, Miyanishi K, Tanaka S, Takada K, Kawano Y, Sakurada A, Sato M, Kubo T, Sato T, Sato Y, Takimoto
R. Increased duodenal iron absorption through upâ€regulation of divalent metal transporter 1 from
enhancement of iron regulatory protein 1 activity in patients with nonalcoholic steatohepatitis. Hepatology.2015 Sep;62(3):751-61. [PubMed] [Google Scholar]
Bozzini C, Girelli D, Olivieri O, Martinelli N, Bassi A, De Matteis G, Tenuti I, Lotto V, Friso S, Pizzolo F, Corrocher
R. Prevalence of body iron excess in the metabolic syndrome. Diabetes Care. 2005 Aug 1;28(8):2061-3.
[PubMed] [Google Scholar]
Jehn M, Clark JM, Guallar E. Serum ferritin and risk of the metabolic syndrome in US adults. Diabetes Care.
Oct 1;27(10):2422-8. [PubMed] [Google Scholar]
Tuomainen TP, Nyyssönen K, Salonen R, Tervahauta A, Korpela H, Lakka T, Kaplan GA, Salonen JT. Body
iron stores are associated with serum insulin and blood glucose concentrations: population study in
,013 eastern Finnish men. Diabetes Care. 1997 Mar 1;20(3):426-8. [PubMed] [Google Scholar]
Piperno A, Trombini P, Gelosa M, Mauri V, Pecci V, Vergani A, Salvioni A, Mariani R, Mancia G. Increased
serum ferritin is common in men with essential hypertension. J Hypertens. 2002 Aug 1;20(8):1513-8.
[PubMed] [Google Scholar]
Aigner E, Theurl I, Theurl M, Lederer D, Haufe H, Dietze O, Strasser M, Datz C, Weiss G. Pathways underlying
iron accumulation in human nonalcoholic fatty liver disease. The Am J Clin Nutr. 2008 May 1;87(5):1374-
[PubMed] [Google Scholar]
Manco M, Alisi A, Real JM, Equitani F, DeVito R, Valenti L, Nobili V. Early interplay of intra-hepatic iron and
insulin resistance in children with non-alcoholic fatty liver disease. J Hepatol. 2011 Sep 1;55(3):647-53.
[PubMed] [Google Scholar]
Otogawa K, Kinoshita K, Fujii H, Sakabe M, Shiga R, Nakatani K, Ikeda K, Nakajima Y, Ikura Y, Ueda M,
Arakawa T. Erythrophagocytosis by liver macrophages (Kupffer cells) promotes oxidative stress, inflammation,
and fibrosis in a rabbit model of steatohepatitis: implications for the pathogenesis of human nonalcoholic
steatohepatitis. Am J Pathol. 2007 Mar 1;170(3):967-80. [PubMed] [Google Scholar]
Copyright (c) 2021 Kuldeep Kumar, Devu R, Rajnish Avasthi, Mukul P Agarwal, Satendra Sharma, Anupama Tandon
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
